Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Plos One|March 9, 2013
5' UTR control of native ERG and of Tmprss2:ERG variants activity in prostate cancerFrancesca Zammarchi, George Boutsalis, Luca Cartegni
Journal for Immunotherapy of Cancer|September 11, 2020
CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunityFrancesca Zammarchi, Karin Havenith, Francois Bertelli, et al.
Oncology Reports|March 8, 2007
Expression of Wnt5A and Wnt10B in non-immortalized breast cancer cellsMariana Fernandez-Cobo, Francesca Zammarchi, John Mandeli, et al.
Molecular Cancer Therapeutics|July 17, 2020
The Role of Specific ATP-Binding Cassette Transporters in the Acquired Resistance to Pyrrolobenzodiazepine Dimer-Containing Antibody-Drug ConjugatesSimon Corbett, Shiran Huang, Francesca Zammarchi, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 19, 2011
Antitumorigenic potential of STAT3 alternative splicing modulationFrancesca Zammarchi, Elisa de Stanchina, Eirini Bournazou, et al.
The American Journal of Pathology|August 23, 2011
A mouse mammary tumor virus env-like exogenous sequence is strictly related to progression of human sporadic breast carcinomaChiara Maria Mazzanti, Mohammad Al Hamad, Giovanni Fanelli, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|March 22, 2024
Integrin-αvβ6 targeted peptide-toxin therapy in a novel αvβ6-expressing immunocompetent model of pancreatic cancerNicholas F Brown, Elizabeth R Murray, Lauren C Cutmore, et al.
Molecular Cancer Therapeutics|January 28, 2022
Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody-drug Conjugate Targeting AXL-expressing CancersFrancesca Zammarchi, Karin Eg Havenith, Simon Chivers, et al.
Future Oncology (London, England)|November 7, 2024
Understanding how CD19 expression levels impact the response to loncastuximab tesirine: a plain language summaryPaolo F Caimi, Mehdi Hamadani, Carmelo Carlo-Stella, et al.
Ejhaem|February 26, 2024
In relapsed or refractory diffuse large B-cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirinePaolo F Caimi, Mehdi Hamadani, Carmelo Carlo-Stella, et al.
Pageof 3